# GlaxoSmithKline and CureVac partner on new mRNA Covid-19 vaccines

- Link: https://www.directorstalkinterviews.com/glaxosmithkline-and-curevac-partner-on-new-mrna-covid-19-vaccines/412958703
- Published: 2021-02-03T07:24:27+00:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
plc** ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
and CureVac N.V. (Nasdaq:CVAC) have announced a new €150m collaboration, building
on their existing relationship, to jointly develop next generation mRNA vaccines
for COVID-19 with the potential for a multi-valent approach to address multiple 
emerging variants in one vaccine.

GSK will also support the manufacture of up to 100 million doses of CureVac’s first
generation COVID-19 vaccine candidate CVnCoV in 2021

Through this new exclusive co-development agreement, GSK and CureVac will contribute
resources and expertise to research, develop, and manufacture a number of novel 
mRNA vaccine candidates, including multi-valent and monovalent approaches. The aim
of this work is to offer broader protection against a variety of different SARS-
CoV2 variants, and to enable a quick response to new variants potentially emerging
in the future. The development programme will begin immediately, with the target
of introducing the vaccine in 2022, subject to regulatory approval.

The increase in emerging variants with the potential to reduce the efficacy of first
generation COVID-19 vaccines requires acceleration of efforts to develop vaccines
against new variants to keep one step ahead of the pandemic. These next generation
COVID-19 vaccines may either be used to protect people who have not been vaccinated
before, or to serve as boosters in the event that COVID-19 immunity gained from 
an initial vaccination reduces over time. In addition, the collaboration will assess
the development of novel mRNA vaccines to protect against multiple respiratory viruses,
including COVID-19.

This collaboration will build on CureVac’s first generation COVID-19 vaccine candidate
CVnCoV, which is currently in Phase 2b/3 clinical trial and on CureVac’s ability
to optimise mRNA for a strong immune response, manufacturability, and stability 
at standard 2-8°C cold chain conditions for vaccines. CureVac’s platform is uniquely
adapted to designing multi-valent vaccines with a balanced immune response and a
low dose of mRNA.

As part of the new collaboration, GSK will also support manufacture of CureVac’s
first-generation COVID-19 vaccine candidate CVnCoV which is currently in Phase 2b/
3 trials. Using its established manufacturing network in Belgium, GSK aims to support
manufacturing of up to 100 million doses of the vaccine in 2021.

Under the terms of the new collaboration agreement, GSK will be the marketing authorisation
holder for the next generation vaccine, except in Switzerland, and will have exclusive
rights to develop, manufacture, and commercialise the next generation COVID-19 vaccine
in all countries with the exception of Germany, Austria and Switzerland. GSK will
make an upfront payment of €75m and a further milestone payment of €75m, conditional
on the achievement of specific milestones.

> **Franz-Werner Haas, Chief Executive Officer of CureVac**, said: “We are very 
> pleased to build on our existing relationship with GSK with a new agreement to
> jointly develop next generation mRNA-based vaccines, in addition to our current
> candidate CVnCoV. With the help of GSK’s proven vaccine expertise, we are equipping
> ourselves to tackle future health challenges with novel vaccines.”

> **Emma Walmsley, Chief Executive Officer, GlaxoSmithKline,** said: “We believe
> that next generation vaccines will be crucial in the continued fight against COVID-
> 19. This new collaboration builds on our existing relationship with CureVac and
> means that together, we will combine our scientific expertise in mRNA and vaccine
> development to advance and accelerate the development of new COVID-19 vaccine 
> candidates. At the same time, we will also support the production of CureVac’s
> first generation vaccines with the manufacture of 100 million doses in 2021.”

Share on: